BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 26651387)

  • 1. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P; Stępniak J
    Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
    Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib in gastrointestinal stromal tumors.
    Sirohi B; Philip DS; Shrikhande SV
    Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib for treatment of advanced gastrointestinal stromal tumors.
    Overton LC; Heinrich MC
    Expert Opin Pharmacother; 2014 Mar; 15(4):549-58. PubMed ID: 24405315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
    Mohammadi M; Gelderblom H
    Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
    [No Abstract]   [Full Text] [Related]  

  • 7. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
    Shirley M; Keating GM
    Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
    Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
    Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.
    Komatsu Y; Doi T; Sawaki A; Kanda T; Yamada Y; Kuss I; Demetri GD; Nishida T
    Int J Clin Oncol; 2015 Oct; 20(5):905-12. PubMed ID: 25655899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
    Son MK; Ryu MH; Park JO; Im SA; Kim TY; Lee SJ; Ryoo BY; Park SR; Kang YK
    Cancer Res Treat; 2017 Apr; 49(2):350-357. PubMed ID: 27456941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib for cancer.
    Strumberg D; Schultheis B
    Expert Opin Investig Drugs; 2012 Jun; 21(6):879-89. PubMed ID: 22577890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
    Lyseng-Williamson KA
    BioDrugs; 2013 Oct; 27(5):525-31. PubMed ID: 23975637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
    Serrano C; Leal A; Kuang Y; Morgan JA; Barysauskas CM; Phallen J; Triplett O; Mariño-Enríquez A; Wagner AJ; Demetri GD; Velculescu VE; Paweletz CP; Fletcher JA; George S
    Clin Cancer Res; 2019 Dec; 25(24):7287-7293. PubMed ID: 31471313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
    George S; Wang Q; Heinrich MC; Corless CL; Zhu M; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Tap WD; Yap JT; Van den Abbeele AD; Manola JB; Solomon SM; Fletcher JA; von Mehren M; Demetri GD
    J Clin Oncol; 2012 Jul; 30(19):2401-7. PubMed ID: 22614970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib-induced hyperammonemic encephalopathy.
    Kuo JC; Parakh S; Yip D
    J Clin Pharm Ther; 2014 Aug; 39(4):446-8. PubMed ID: 24707992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
    Kang YK; George S; Jones RL; Rutkowski P; Shen L; Mir O; Patel S; Zhou Y; von Mehren M; Hohenberger P; Villalobos V; Brahmi M; Tap WD; Trent J; Pantaleo MA; Schöffski P; He K; Hew P; Newberry K; Roche M; Heinrich MC; Bauer S
    J Clin Oncol; 2021 Oct; 39(28):3128-3139. PubMed ID: 34343033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib.
    Ettrich TJ; Seufferlein T
    Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.